Onyx Pharma set to buy Proteolix for up to $851M
Onyx Pharmaceuticals, developer of treatments for liver and late-stage kidney cancer, has moved to acquire Proteolix, provider of a technology that can accelerate the death of cancer cells, for as much as $851 million. Emeryville, Calif.-based Onyx says it wants to incorporate this component, which… Continue Reading
Life sciences briefing: Thursday, Feb. 14, 2008
TODAY’S HEADLINES:
Arbor Surgical draws another $5.5M for heart-valve replacements (VBLS exclusive)
AstraZeneca spinout Albireo raises $27M for GI drugs (release)
Knee-implant maker MAKO Surgical slashes IPO price range (release)
eScreen takes in $8M for automated drug screening (peHUB)
GlucoLight gets undisclosed funding for glucose monitoring (release)
Oddo et al. order… Continue Reading
Life sciences briefing: Thursday, Nov. 15, 2007
Featured companies: BioVex, FullTurn Media, Humanetics, N Spine, Novitas Capital, Reliant Technologies, Symbios, Vaxart, Virtual Radiologic, Winston Laboratories, Zosano Pharma
EXPANDING ITEMS: Stay tuned.
Vaxart receives $3.3M for oral vaccines — San Francisco’s Vaxart, a biotech developing novel adenovirus-based vaccines, raised $2.7 million in a first funding round. Vaxart… Continue Reading
Life sciences briefing: Thursday, Oct. 25, 2007
Featured companies: BioVex, Cavadis, Innovention, Paratek Pharmaceuticals, Phase Bioscience, Reliant Pharmaceuticals, Xencor
UPDATED: Expanded Paratek and Xencor items.
Paratek Pharma raises $40M for new antibiotics — Boston’s Paratek Pharmaceuticals, a biotech working on new antibiotics to treat drug-resistant bacterial infections, raised a first tranche of a $40 million eighth… Continue Reading
Drug delivery co., Macroflux, raises $75M
Macroflux Corp., a Mountain View developer of drug delivery technology using patches, has raised $75 million in first-round funding, as it spins out from Johnson & Johnson subsidiary ALZA Corp.
Nomura Phase4 Ventures led the deal, and was joined by New Enterprise Associates and HBM… Continue Reading